222 related articles for article (PubMed ID: 18818134)
1. Current role of radionuclide imaging in differentiated thyroid cancer.
Wong KT; Choi FP; Lee YY; Ahuja AT
Cancer Imaging; 2008 Sep; 8(1):159-62. PubMed ID: 18818134
[TBL] [Abstract][Full Text] [Related]
2. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 18fluoro-2-deoxyglucose positron emission tomography in iodine scan negative, differentiated thyroid cancer recurrence.
Chisholm EJ; Tolley NS
J Laryngol Otol; 2009 Oct; 123(10):1145-9. PubMed ID: 19607742
[TBL] [Abstract][Full Text] [Related]
4. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
Ong SC; Ng DC; Sundram FX
Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
[TBL] [Abstract][Full Text] [Related]
5. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
Cabrera Martín MN; Pasamontes Pingarrón JA; Carreras Delgado JL; Lapeña Gutiérrez L; Delgado Bolton RC; Bittini Copano A; Pérez Castejón MJ; Fernández Pérez C
Rev Esp Med Nucl; 2007; 26(5):263-9. PubMed ID: 17910834
[TBL] [Abstract][Full Text] [Related]
7. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.
Haslerud T; Brauckhoff K; Reisæter L; Küfner Lein R; Heinecke A; Varhaug JE; Biermann M
Acta Radiol; 2016 Oct; 57(10):1193-200. PubMed ID: 26163534
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET of thyroid nodules with inconclusive cytologic results.
Martínez-Duncker C; Hurtado-López LM
J Nucl Med; 2006 Sep; 47(9):1555; author reply 1555-6. PubMed ID: 16954566
[No Abstract] [Full Text] [Related]
10. FDG PET and alternative imaging in the management of thyroid carcinoma.
Al-Nahhas AM
Nucl Med Rev Cent East Eur; 2003; 6(2):139-45. PubMed ID: 14737730
[TBL] [Abstract][Full Text] [Related]
11. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
Alzahrani AS; Abouzied ME; Salam SA; Mohamed G; Rifai A; Al Sugair A; Amin T
Eur J Endocrinol; 2008 May; 158(5):683-9. PubMed ID: 18426827
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose and 131I radioguided surgical management of thyroid cancer.
Francis CL; Nalley C; Fan C; Bodenner D; Stack BC
Otolaryngol Head Neck Surg; 2012 Jan; 146(1):26-32. PubMed ID: 21952355
[TBL] [Abstract][Full Text] [Related]
13. Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy.
Al-Nahhas A; Khan S; Gogbashian A; Banti E; Rampin L; Rubello D
In Vivo; 2008; 22(1):109-14. PubMed ID: 18396792
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
London K; Lin M
Ann Surg Oncol; 2011 Jan; 18(1):291. PubMed ID: 20505997
[No Abstract] [Full Text] [Related]
15. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
[TBL] [Abstract][Full Text] [Related]
16. Conventional gamma and high energy probe for radioguided dissection of metastases in a patient with recurrent thyroid carcinoma with (99m)Tc-MIBI and (18)F-FDG.
Meller B; Sahlmann C; Horstmann O; Gerl J; Baehre M; Meller J
Nuklearmedizin; 2005; 44(3):N23-5. PubMed ID: 15997503
[No Abstract] [Full Text] [Related]
17. Clinical usefulness of FDG PET in differentiated thyroid cancer.
Macapinlac HA
J Nucl Med; 2001 Jan; 42(1):77-8. PubMed ID: 11197984
[No Abstract] [Full Text] [Related]
18. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
19. PET in the follow-up of differentiated thyroid cancer.
Khan N; Oriuchi N; Higuchi T; Zhang H; Endo K
Br J Radiol; 2003 Oct; 76(910):690-5. PubMed ID: 14512328
[TBL] [Abstract][Full Text] [Related]
20. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
